Tourette Syndrome Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Tourette Syndrome Clinical Trials Market Report Overview
The Tourette Syndrome clinical trial market research report provides an overview of the Tourette Syndrome Clinical trials scenario. This report provides top-line data relating to the clinical trials on Tourette Syndrome and includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report also offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type. It provides prominent drugs for in-progress trials (based on the number of ongoing trials).
Key Regions | · North America
· Asia-Pacific · Europe · Middle East & Africa · South & Central America |
Key Countries | · The US
· China · Germany · Canada · Hungary · Italy · South Korea · Spain · Australia · Poland |
Key Sponsor Types | · Institution
· Company · Government |
Leading Sponsors | · Neurocrine Biosciences Inc
· Teva Pharmaceutical Industries Ltd · Otsuka Holdings Co Ltd · Emalex Biosciences Inc · Syneos Health Inc · The Lundbeck Foundation · Laboratory Corp of America Holdings · C. H. Boehringer Sohn AG & Co KG · Catalyst Pharmaceuticals Inc · Allucent |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Tourette Syndrome Clinical Trials Market Segmentation by Regions and Countries
The key regions in the Tourette Syndrome clinical trials market are North America, Asia-Pacific, Europe, the Middle East & Africa, and South & Central America, among others. North America dominates the market as of June 2023.
In a country-wise analysis, as of June 2023, the US has the highest number of Tourette Syndrome clinical trials, followed by China, Germany, Canada, Hungary, Italy, South Korea, Spain, Australia, and Poland.
G7 countries: Among the G7 (United States, United Kingdom, Germany, France, Italy, Canada, and Japan) countries, Germany has the highest proportion of Tourette Syndrome to Central Nervous System clinical trials as of June 2023. Moreover, most of the clinical trials were conducted in the US.
E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Mexico has the highest proportion of Tourette Syndrome to Central Nervous System clinical trials as of June 2023. Out of all the clinical trials conducted in the E7 countries, the majority were in China.
Tourette Syndrome Clinical Trials Analysis by Regions, 2023 (%)
For more regional insights into the Tourette Syndrome clinical trials market, download a free report sample
Tourette Syndrome Clinical Trials Market Segmentation by Sponsor Types
The key sponsor types in the Tourette Syndrome clinical trials market are institution, company, and the government. Out of them, the company sponsor type dominates the market, followed by institution.
Tourette Syndrome Clinical Trials Market Analysis by Sponsor Types, 2023 (%)
For more sponsor type insights into the Tourette Syndrome clinical trials market, download a free report sample
Tourette Syndrome Clinical Trials Market - Competitive Landscape
The leading sponsors in the Tourette Syndrome clinical trials market are Neurocrine Biosciences Inc, Teva Pharmaceutical Industries Ltd, Otsuka Holdings Co Ltd, Emalex Biosciences Inc, Syneos Health Inc, The Lundbeck Foundation, Laboratory Corp of America Holdings, C. H. Boehringer Sohn AG & Co KG, Catalyst Pharmaceuticals Inc, and Allucent. Neurocrine Biosciences Inc led the Tourette Syndrome clinical trials market in June 2023.
Tourette Syndrome Clinical Trials Market Analysis by Sponsors, 2023 (%)
To know more about the leading sponsors in the Tourette Syndrome clinical trials market, download a free report sample
Segments Covered in the Report
Tourette Syndrome Clinical Trials Regional Outlook (2023)
- North America
- Asia-Pacific
- Europe
- Middle East & Africa
- South & Central America
Tourette Syndrome Clinical Trials Country Outlook (2023)
- The US
- China
- Germany
- Canada
- Hungary
- Italy
- South Korea
- Spain
- Australia
- Poland
Tourette Syndrome Clinical Trials Sponsor Type Outlook (2023)
- Institution
- Company
- Government
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type, and End point status
- The report reviews the top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended, and Withdrawn) with a reason for unaccomplishment
- The report provides enrollment trends for the past five years
- Report provides the latest news for the past three months
Reasons to Buy
- Assists in formulating key business strategies with regard to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top-level analysis of the Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trial count and enrollment trends by country in the global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional, and country level
Teva Pharmaceutical Industries Ltd
Otsuka Holdings Co Ltd
Emalex Biosciences Inc
Syneos Health Inc
The Lundbeck Foundation
Laboratory Corp of America Holdings
C. H. Boehringer Sohn AG & Co KG
Catalyst Pharmaceuticals Inc
Allucent
Table of Contents
Table
Figures
Frequently asked questions
-
Which is the leading region in the Tourette Syndrome clinical trials market?
North America is the leading region in the Tourette Syndrome clinical trials market as of June 2023.
-
Which is the leading country in the Tourette Syndrome clinical trials market?
The US is the leading country in the Tourette Syndrome clinical trials market as of June 2023.
-
Which is the leading sponsor type in the Tourette Syndrome clinical trials market?
Company is the leading sponsor type in the Tourette Syndrome clinical trials market as of June 2023.
-
Who are the leading sponsors in the Tourette Syndrome clinical trials market?
The leading sponsors in the Tourette Syndrome clinical trials market are Neurocrine Biosciences Inc, Teva Pharmaceutical Industries Ltd, Otsuka Holdings Co Ltd, Emalex Biosciences Inc, Syneos Health Inc, The Lundbeck Foundation, Laboratory Corp of America Holdings, C. H. Boehringer Sohn AG & Co KG, Catalyst Pharmaceuticals Inc, and Allucent.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.